Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Clusterin Rat ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Apolipoprotein J, Apo J
  • Species:Rat
Please select your region to see available products and prices.
Cat. No. Size Price

Clearance sale RD391034200CS 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Urine

Sample Requirements

5 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

4–128 ng/ml

Limit of Detection

Limit of detection(LOD) (defined as concentration of analyte giving absorbance higher than mean absorbance of blank* plus three standard deviations of the absorbance of blank: Ablank + 3×SDblank) is 0.7 ng/ml.

Intra-assay (Within-Run)

n = 8; CV = 4.4%

Inter-assay (Run-to-Run)

n = 8; CV = 5.9%

Spiking Recovery


Dilution Linearity



  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • human Non-detectable
  • monkey Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • rat Yes
  • mouse Yes (recommended dilution 1:500)


  • It is intended for research use only.
  • The total assay time is less than 3.5 hours.
  • The kit measures Clusterin in rat serum and rat urine.
  • Assay format - 96 wells
  • Quality Controls are rat serum based. No human sera are used.
  • Standard is recombinant protein based.
  • Components of the kit are provided ready to use, concentrated or lyophilized.

Research topic

Neural tissue markers, Oncology, Others, Renal disease, Sepsis, Animal studies


Clusterin (Apolippoprotein J; SP-40,40; TRPM-2; SGP-2; pADHC-9; CLJ; T64; GP III; XIP8) is a highly conserved disulfide-linked secreted heterodimeric glycoprotein of 75-80 kDa but truncated forms targeted to the nucleus have also been identified.
The protein is constitutively secreted by a number of cell types including epithelial and neuronal cells and is a major protein in physiological fluids including plasma, milk, urine, cerebrospinal fluid and semen. Due to its wide breath of tissue distribution many diverse physiological functions have been attributed to Clusterin including sperm maturation, membrane recycling, lipid transportation, tissue remodelling, complement inhibition and cell-cell or cell-substratum interactions. Moreover, it was proposed that Clusterin functions as an extracellular chaperon that stabilizes stressed proteins in a folding-competent state, and that the protein is involved in programmed cell death. Another defining prominent function of Clusterin is its induction in many severe physiological disturbances states including kidney degenerative diseases, prostate and vesicle carcinogenesis, ovarian cancer and several neurodegenerative conditions (Alzheimer’s disease).
Recent study demonstrates, that serum Clusterin level increases significantly in diabetic type II patients and in patients with developing coronary heart disease, or myocardial infarction. These data raise the possibility that elevated Clusterin levels in serum may represent a strong indication of vascular damage.
In patients with systemic lupus erythematosus (SLE), reduced serum Clusterin levels correlated inversely with disease activity. Lowered Clusterin levels could be involved in the pathogeneses of SLE on account of decreased protective effects.
Another interesting observation obtained in rat model suggests that measurement of urinary Clusterin levels may be a useful clinical marker for the severity of renal tubular damage. Furthermore, urinary Clusterin may also help to differentiate between tubular and glomerular forms of proteinuria.

Areas of investigation:
Coronary heart diseases, Myocardial infarction, Neurodegenerative diseases, Kidney degenerative disease, Renal tubular damage

Product References (6)


  • Adler M, Hoffmann D, Ellinger-Ziegelbauer H, Hewitt P, Matheis K, Mulrane L,Gallagher WM, Callanan JJ, Suter L, Fountoulakis MM, Dekant W, Mally A.Assessment of candidate biomarkers of drug-induced hepatobiliary injury inpreclinical toxicity studies. Toxicol Lett. 2010 Jun 16;196(1):1-11. doi:10.1016/j.toxlet.2010.03.018. Epub 2010 Apr 1. PubMed PMID: 20362651. See more on PubMed
  • Hoffmann D, Adler M, Vaidya VS, Rached E, Mulrane L, Gallagher WM, CallananJJ, Gautier JC, Matheis K, Staedtler F, Dieterle F, Brandenburg A, Sposny A,Hewitt P, Ellinger-Ziegelbauer H, Bonventre JV, Dekant W, Mally A. Performance ofnovel kidney biomarkers in preclinical toxicity studies. Toxicol Sci. 2010Jul;116(1):8-22. doi: 10.1093/toxsci/kfq029. Epub 2010 Jan 29. PubMed PMID:20118187; PubMed Central PMCID: PMC2886853. See more on PubMed
  • Sieber M, Hoffmann D, Adler M, Vaidya VS, Clement M, Bonventre JV, Zidek N,Rached E, Amberg A, Callanan JJ, Dekant W, Mally A. Comparative analysis of novelnoninvasive renal biomarkers and metabonomic changes in a rat model of gentamicinnephrotoxicity. Toxicol Sci. 2009 Jun;109(2):336-49. doi: 10.1093/toxsci/kfp070. Epub 2009 Apr 6. PubMed PMID: 19349640; PubMed Central PMCID: PMC4830225. See more on PubMed
  • Vinken P, Starckx S, Barale-Thomas E, Looszova A, Sonee M, Goeminne N,Versmissen L, Buyens K, Lampo A. Tissue Kim-1 and urinary clusterin as earlyindicators of cisplatin-induced acute kidney injury in rats. Toxicol Pathol. 2012Oct;40(7):1049-62. Epub 2012 May 11. PubMed PMID: 22581811. See more on PubMed
  • Zhang F, Sha J, Wood TG, Galindo CL, Garner HR, Burkart MF, Suarez G, SierraJC, Agar SL, Peterson JW, Chopra AK. Alteration in the activation state of newinflammation-associated targets by phospholipase A2-activating protein (PLAA).Cell Signal. 2008 May;20(5):844-61. doi: 10.1016/j.cellsig.2008.01.004. Epub 2008Jan 17. PubMed PMID: 18291623; PubMed Central PMCID: PMC2729133. See more on PubMed
  • Vange P, Bruland T, Doseth B, Fossmark R, Sousa MML, Beisvag V, Sørdal Ø,Qvigstad G, Waldum HL, Sandvik AK, Bakke I. The cytoprotective protein clusterin is overexpressed in hypergastrinemic rodent models of oxyntic preneoplasia andpromotes gastric cancer cell survival. PLoS One. 2017 Sep 13;12(9):e0184514. doi:10.1371/journal.pone.0184514. eCollection 2017. PubMed PMID: 28902909; PubMedCentral PMCID: PMC5597207. See more on PubMed
Summary References (13)

References to Clusterin

  • Choi-Miura NH, Oda T: Relationship between multifunctional protein Clusterin and Alzheimer disease. Neurobiol. Aging 1996; 17(5): 717–722
  • Newkirk MM, Apostolakos P, Neville C and Fortin PR: Systemic lupus erythematosus, a disease associated with low levels of Clusterin/ApoJ, and anti-inflammatory protein. J. Rheumatol.1999; 3:597–603
  • Morrissey C, Lakins J, Moquin A, Hussain M, Tenniswood M: An antigen capture assay for the measurement of serum Clusterin concentrations. J. Biochen. Biophys. Methods 2001; 48:13–21
  • Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES: Serum levels of the senescence biomarker Clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Ex. Gerontology 2002; 37: 1175–1187
  • Jones SE, Jomary C: Molecules in focus Clusterin. The International J. of Bioch. & Cell Biol. 2002; 34:427–431
  • Hidaka S, Kränzlin B, Gretz N, Witzgall R: Urinary Clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res. 2002; 310:289–296
  • Chen X, Halberg RB, Ehrhardt WM, Torrealba J and Dove WF: Clusterin as a biomarker in murine and human intestinal neoplasia. PNAS 2003; 100:9530–9535
  • Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y, Wu M, Qian XH and Zhao XH: Loss of Clusterin both in serum and tissue correlates with the tumorogenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003; 9:650–654
  • Wang L, Erling P, Bengtsson AA, Truedsson L, Sturfelt G, Erlinge D: Transcriptional down-regulation of the platelet ADP receptory P2Y12 and Clusterin in patients with systemic lupus erythematosus. J. of Thromb. And Haemost. 2004; 2:1436–1442
  • Patel NV, Wei M, Wong A, Finch CE, Morgan TE: Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neuroscience Letters 2004; 371:199–204
  • Kim BM, Kim SY, Lee S, Shin YJ, Min BH, Bendayan M, Park IS: Clusterin induces differentiation of pancreatic duct calls into insulin-secreting cells. Diabetologia 2006; 49:311–320
  • Kruger S, Mahnken A, Kausch I, Feller AC: Value of Clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006; 67:105–109
  • Stejskal D, Fiala R: Evaluation of serum and urine Clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 2006; 53:343–34
Related Products Docs